|
시장보고서
상품코드
1504940
암 악액질 시장, 점유율, 규모, 동향, 산업 분석 리포트 : 요법별, 작용기서별, 유통 채널별, 지역별, 부문별 예측(2024-2032년)Cancer Cachexia Market Share, Size, Trends, Industry Analysis Report, By Therapeutics (Progestogens, Corticosteroids, Combination Therapy, and Others); By Mechanism of Action; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032 |
||||||
Polaris Market Research의 최신 조사에 따르면 세계의 암 악액질 시장 규모는 2032년까지 34억 3,000만 달러에 달할 전망입니다. 이 리포트는 현재 시장 역학에 대한 상세 인사이트를 제시하고, 향후 시장 성장에 관한 분석을 제공하고 있습니다.
특히 노년층에서 암 유병률의 급격한 증가와 악액질의 중요성에 대한 의료 전문가들의 인식이 높아지면서 세계 시장 성장에 기여하고 있습니다. 암 환자가 증가함에 따라 암 악액질 발생 위험도 증가하고 있습니다.
예를 들어 GLOBOCAN 2022 데이터에 따르면 2022년 암에 걸린 사람의 53% 이상이 65세 이상입니다. 전 세계 고령화 인구가 빠르게 증가하여 2022년에는 7억 6,000만 명, 2050년에는 16억 명으로 증가할 것으로 예상되기 때문에 암의 유병률도 증가할 가능성이 높습니다.
암 연구를 지원하고 첨단 치료법과 약품 시장 개척을 촉진하기 위한 정부의 구상도 증가하고 있으며, 이는 시장 성장을 가속하고 있습니다. 암 악액질에 대응하기 위해 특별히 개발된 새로운 치료법 개발에 참여하고 있는 주요 제약사들이 있습니다.
예를 들어 2023년 8월 액티메드 테라퓨틱스(Actimed Therapeutics)는 암 악액질 및 기타 여러 근육 소모성 질환 치료를 위해 475만 파운드를 조달했다고 발표했습니다. 이 자금은 회사의 개발을 지속하고 IMPACT 임상 개발 프로그램의 준비를 보장하기 위해 활용될 예정입니다.
암은 40-79세 사망원인 1위이며, 암 환자의 80%가 악액질과 관련이 있고, 약 20%의 환자가 암 악액질로 인해 사망합니다. 이 복잡한 병태생리에 대한 더 많은 연구와 악액질과 관련된 특정 분자 경로를 겨냥한 표적 치료제의 개발이 절실히 요구되고 있습니다.
예를 들어 2023년 9월 액티메드 테라퓨틱스(Actimed Therapeutics)는 비소세포폐암 환자를 대상으로 한 악액질 치료제 S-pindolol benzoate의 임상 2b/3상 IND 신청이 미국 FDA의 승인을 받았다고 발표했습니다.
암 악액질 시장 보고서 하이라이트
2023년 황체 호르몬제 부문은 높은 치료 효율성과 항염증 효과로 인해 주목할 만한 점유율을 차지했습니다.
식욕 자극제 부문은 2023년 대부분의 점유율을 차지했는데, 이는 암 환자들이 체형과 체격을 유지하기 위해 암 환자들에게 널리 채택되고 있기 때문으로 분석됩니다.
유통 채널로 분류되는 온라인 약국 부문은 처방전 관리, 시간 절약 등의 기능으로 인해 온라인 약국의 인기가 높아짐에 따라 예측 기간 중 가장 높은 CAGR로 성장할 것으로 예상됩니다.
북미는 탄탄한 의료 인프라가 구축되어 있고, 암 유병률이 높아 세계 시장을 독점하고 있습니다.
주요 시장 기업은 Aeterna Zentaris, ANI Pharmaceuticals, Merck &Co.Inc., TCI Peptide Therapeutics, Teva Pharmaceutical Industries 등입니다.
목차
제1장 서론
- 리포트 개요
- 조사 목적
- 시장 범위
- 전제조건
- 이해관계자
제2장 주요 요약
제3장 조사 방법
제4장 세계의 암 악액질 시장 인사이트
- 유통 채널 스냅숏
- 암 악액질 시장 역학
- 촉진요인과 기회
- 암 악액질의 이환율 증가가 세계 시장의 성장을 촉진
- 연구개발 활동에 대한 투자 증가가 시장의 성장을 촉진
- 억제요인과 과제
- 고액의 치료비와 엄격한 규제
- 촉진요인과 기회
- PESTEL 분석
- 암 악액질 시장의 유통 채널 동향
- 밸류체인 분석
- COVID-19의 영향 분석
제5장 세계의 암 악액질 시장 : 요법별
- 주요 조사 결과
- 서론
- 프로게스토겐
- 코르티코스테로이드
- 병용요법
- 기타
제6장 세계의 암 악액질 시장 : 작용기서별
- 주요 조사 결과
- 서론
- 식욕 증진제
- 체중감량 안정제
제7장 세계의 암 악액질 시장 : 유통 채널별
- 주요 조사 결과
- 서론
- 병원 약국
- 소매 약국
- 온라인 약국
제8장 세계의 암 악액질 시장 : 지역별
- 주요 조사 결과
- 서론
- 암 악액질 시장 평가 : 지역별,2019-2032년
- 북미
- 북미 : 요법별, 2019-2032년
- 북미 : 유통 채널별, 2019-2032년
- 북미 : 작용기서별, 2019-2032년
- 미국
- 캐나다
- 유럽
- 유럽 : 요법별, 2019-2032년
- 유럽 : 유통 채널별,2019-2032년
- 유럽 : 작용기서별,2019-2032년
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 아시아태평양
- 아시아태평양 : 요법별, 2019-2032년
- 아시아태평양 : 유통 채널별, 2019-2032년
- 아시아태평양 : 작용기서별, 2019-2032년
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 중동 및 아프리카
- 중동 및 아프리카 : 요법별, 2019-2032년
- 중동 및 아프리카 : 유통 채널별,2019-2032년
- 중동 및 아프리카 : 작용기서별, 2019-2032년
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 남아프리카공화국
- 라틴아메리카
- 라틴아메리카 : 요법별, 2019-2032년
- 라틴아메리카 : 유통 채널별,2019-2032년
- 라틴아메리카 : 작용기서별,2019-2032년
- 멕시코
- 브라질
- 아르헨티나
제9장 경쟁 구도
- 확대와 인수의 분석
- 확대
- 인수
- 제휴/협업/합의/공개
제10장 기업 개요
- AbbVie Inc.(US)
- Actimed Therapeutics(UK)
- Aeterna Zentaris Inc.(Canada)
- ANI Pharmaceuticals Inc.(US)
- Aphios Corporation(US)
- Aveo Pharmaceuticals Inc.(US)
- Bristol-Myers Squibb Company(US)
- Helsinn Group(Switzerland)
- Hikma Pharmaceuticals PLC(UK)
- Merck & Co. Inc.(US)
- Mylan N.V.(US)
- Pfizer Inc.(US)
- TCI Peptide Therapeutics(US)
- Teva Pharmaceutical Industries Ltd.(Israel)
The global cancer cachexia market size is expected to reach USD 3.43 billion by 2032, according to a new study by Polaris Market Research. The report "Cancer Cachexia Market Share, Size, Trends, Industry Analysis Report, By Therapeutics (Progestogens, Corticosteroids, Combination Therapy, and Others); By Mechanism of Action; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The drastic increase in the prevalence of cancer, especially among the geriatric population, and growing awareness among healthcare professionals about the significance of cachexia contribute to the global market growth. With the increase in cancer patients, the risk of developing cancer cachexia among individuals also rises.
For instance, according to the GLOBOCAN 2022 data, more than 53% of people who had cancer in 2022 were aged 65 years or above. As the world's ageing population is growing rapidly, with 760 million people in 2022, and is expected to rise to 1.6 billion people by 2050, the prevalence of cancer is also likely to increase.
A growing number of government initiatives supporting cancer research and promoting the development of advanced therapies and drugs also propelled the market's growth. There are key pharmaceutical companies involved in the development of new novel therapies that are specifically developed for addressing cancer cachexia.
For instance, in August 2023, Actimed Therapeutics, announced that they have raised £4.75 million for the treatment of cancer cachexia and many other muscle wasting disorders. The fund will be utilized to continue the development of the company and ensure the preparation of the IMPACT clinical development program.
Cancer remains the leading cause of death for people between the ages of 40-79 years old, and 80% of cancer cases are associated with cachexia, and approx. 20% of patients die due to cancer cachexia; there is a significant need for further studies regarding its complex condition and the development of targeted therapies that are aimed at the specific molecular pathways associated with cachexia.
For instance, in September 2023, Actimed Therapeutics, announced that they have received approval from US FDA for their IND application for Phase 2b/3 clinical study of the S-pindolol benzoate for the treatment of cachexia that are associated with patients with non-small cell lung cancer.
Cancer Cachexia Market Report Highlights
The Progestogens segment accounted for a notable share in 2023, on account of its greater efficiency in treatment and the presence of anti-inflammatory properties.
Appetite stimulators segment held the majority share in 2023, which is attributed to its widespread adoption by cancer patients for maintaining body shape and mass.
The online pharmacy segment categorized under the distribution channel is predicted to grow at the highest CAGR during the forecast period due to the growing popularity of online pharmacies due to its features like prescription management and time-saving.
North America dominated the global market, owing to the presence of well-established healthcare infrastructure and the significant prevalence of cancer.
The key market players include Aeterna Zentaris, ANI Pharmaceuticals, Merck & Co. Inc., TCI Peptide Therapeutics, and Teva Pharmaceutical Industries.
Polaris Market Research has segmented the cancer cachexia market report based on therapeutics, mechanism of action, distribution channel, and region:
Cancer Cachexia, Therapeutics Outlook (Revenue - USD Billion, 2024 - 2032)
- Progestogens
- Corticosteroids
- Combination Therapy
- Others
Cancer Cachexia, Mechanism of Action Outlook (Revenue - USD Billion, 2024 - 2032)
- Appetite Stimulators
- Weight Loss Stabilizers
Cancer Cachexia, Distribution Channel Outlook (Revenue - USD Billion, 2024 - 2032)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Cancer Cachexia, Regional Outlook (Revenue - USD Billion, 2024 - 2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Australia
- Rest of Asia Pacific
- Latin America
- Argentina
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
- Rest of Middle East and Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Cancer Cachexia Market Insights
- 4.1. Cancer Cachexia Market - Distribution Channel Snapshot
- 4.2. Cancer Cachexia Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increasing prevalence of cancer cachexia cases to drive global market growth
- 4.2.1.2. Rising investments in R&D activities spurring market growth
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High treatment costs and stringent regulations
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Cancer Cachexia Market Distribution Channel Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Cancer Cachexia Market, by Therapeutics
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
- 5.3. Progestogens
- 5.3.1. Global Cancer Cachexia Market, by Progestogens, by Region, 2019-2032 (USD Billion)
- 5.4. Corticosteroids
- 5.4.1. Global Cancer Cachexia Market, by Corticosteroids, by Region, 2019-2032 (USD Billion)
- 5.5. Combination Therapy
- 5.5.1. Global Cancer Cachexia Market, by Combination Therapy, by Region, 2019-2032 (USD Billion)
- 5.6. Others
- 5.6.1. Global Cancer Cachexia Market, by Others, by Region, 2019-2032 (USD Billion)
6. Global Cancer Cachexia Market, by Mechanism of Action
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
- 6.3. Appetite Stimulators
- 6.3.1. Global Cancer Cachexia Market, by Appetite Stimulators, by Region, 2019-2032 (USD Billion)
- 6.4. Weight Loss Stabilizers
- 6.4.1. Global Cancer Cachexia Market, by Weight Loss Stabilizers, by Region, 2019-2032 (USD Billion)
7. Global Cancer Cachexia Market, by Distribution Channel
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
- 7.3. Hospital Pharmacy
- 7.3.1. Global Cancer Cachexia Market, by Hospital Pharmacy, By Region, 2019-2032 (USD Billion)
- 7.4. Retail Pharmacy
- 7.4.1. Global Cancer Cachexia Market, by Retail Pharmacy, By Region, 2019-2032 (USD Billion)
- 7.5. Online Pharmacy
- 7.5.1. Global Cancer Cachexia Market, by Online Pharmacy, By Region, 2019-2032 (USD Billion)
8. Global Cancer Cachexia Market, by Geography
- 8.1. Key findings
- 8.2. Introduction
- 8.2.1. Cancer Cachexia Market Assessment, By Geography, 2019-2032 (USD Billion)
- 8.3. Cancer Cachexia Market - North America
- 8.3.1. North America: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
- 8.3.2. North America: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.3.3. North America: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
- 8.3.4. Cancer Cachexia Market - U.S.
- 8.3.4.1. U.S.: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
- 8.3.4.2. U.S.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.3.4.3. U.S.: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
- 8.3.5. Cancer Cachexia Market - Canada
- 8.3.5.1. Canada: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
- 8.3.5.2. Canada.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.3.5.3. Canada: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
- 8.4. Cancer Cachexia Market - Europe
- 8.4.1. Europe: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
- 8.4.2. Europe.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4.3. Europe: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
- 8.4.4. Cancer Cachexia Market - UK
- 8.4.4.1. UK: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
- 8.4.4.2. UK.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4.4.3. UK: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
- 8.4.5. Cancer Cachexia Market - France
- 8.4.5.1. France: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
- 8.4.5.2. France.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4.5.3. France: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
- 8.4.6. Cancer Cachexia Market - Germany
- 8.4.6.1. Germany: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
- 8.4.6.2. Germany.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4.6.3. Germany: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
- 8.4.7. Cancer Cachexia Market - Italy
- 8.4.7.1. Italy: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
- 8.4.7.2. Italy.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4.7.3. Italy: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
- 8.4.8. Cancer Cachexia Market - Spain
- 8.4.8.1. Spain: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
- 8.4.8.2. Spain.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4.8.3. Spain: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
- 8.4.9. Cancer Cachexia Market - Netherlands
- 8.4.9.1. Netherlands: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
- 8.4.9.2. Netherlands.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4.9.3. Netherlands: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
- 8.4.10. Cancer Cachexia Market - Russia
- 8.4.10.1. Russia: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
- 8.4.10.2. Russia.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4.10.3. Russia: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
- 8.5. Cancer Cachexia Market - Asia Pacific
- 8.5.1. Asia Pacific: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
- 8.5.2. Asia Pacific.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.5.3. Asia Pacific: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
- 8.5.4. Cancer Cachexia Market - China
- 8.5.4.1. China: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
- 8.5.4.2. China.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.5.4.3. China: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
- 8.5.5. Cancer Cachexia Market - India
- 8.5.5.1. India: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
- 8.5.5.2. India.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.5.5.3. India: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
- 8.5.6. Cancer Cachexia Market - Malaysia
- 8.5.6.1. Malaysia: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
- 8.5.6.2. Malaysia.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.5.6.3. Malaysia: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
- 8.5.7. Cancer Cachexia Market - Japan
- 8.5.7.1. Japan: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
- 8.5.7.2. Japan.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.5.7.3. Japan: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
- 8.5.8. Cancer Cachexia Market - Indonesia
- 8.5.8.1. Indonesia: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
- 8.5.8.2. Indonesia.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.5.8.3. Indonesia: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
- 8.5.9. Cancer Cachexia Market - South Korea
- 8.5.9.1. South Korea: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
- 8.5.9.2. South Korea.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.5.9.3. South Korea: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
- 8.6. Cancer Cachexia Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
- 8.6.2. Middle East & Africa.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.6.3. Middle East & Africa: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
- 8.6.4. Cancer Cachexia Market - Saudi Arabia
- 8.6.4.1. Saudi Arabia: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
- 8.6.4.2. Saudi Arabia.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.6.4.3. Saudi Arabia: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
- 8.6.5. Cancer Cachexia Market - UAE
- 8.6.5.1. UAE: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
- 8.6.5.2. UAE.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.6.5.3. UAE: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
- 8.6.6. Cancer Cachexia Market - Israel
- 8.6.6.1. Israel: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
- 8.6.6.2. Israel.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.6.6.3. Israel: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
- 8.6.7. Cancer Cachexia Market - South Africa
- 8.6.7.1. South Africa: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
- 8.6.7.2. South Africa.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.6.7.3. South Africa: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
- 8.7. Cancer Cachexia Market - Latin America
- 8.7.1. Latin America: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
- 8.7.2. Latin America.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.7.3. Latin America: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
- 8.7.4. Cancer Cachexia Market - Mexico
- 8.7.4.1. Mexico: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
- 8.7.4.2. Mexico.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.7.4.3. Mexico: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
- 8.7.5. Cancer Cachexia Market - Brazil
- 8.7.5.1. Brazil: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
- 8.7.5.2. Brazil.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.7.5.3. Brazil: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
- 8.7.6. Cancer Cachexia Market - Argentina
- 8.7.6.1. Argentina: Cancer Cachexia Market, by Therapeutics, 2019-2032 (USD Billion)
- 8.7.6.2. Argentina.: Cancer Cachexia Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.7.6.3. Argentina: Cancer Cachexia Market, by Mechanism of Action, 2019-2032 (USD Billion)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. AbbVie Inc. (US)
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Actimed Therapeutics (UK)
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3.Aeterna Zentaris Inc. (Canada)
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. ANI Pharmaceuticals Inc. (US)
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Aphios Corporation (US)
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Aveo Pharmaceuticals Inc. (US)
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Bristol-Myers Squibb Company (US)
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Helsinn Group (Switzerland)
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Hikma Pharmaceuticals PLC (UK)
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Merck & Co. Inc. (US)
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
- 10.11. Mylan N.V. (US)
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development
- 10.12. Pfizer Inc. (US)
- 10.12.1. Company Overview
- 10.12.2. Financial Performance
- 10.12.3. Product Benchmarking
- 10.12.4. Recent Development
- 10.13. TCI Peptide Therapeutics (US)
- 10.13.1. Company Overview
- 10.13.2. Financial Performance
- 10.13.3. Product Benchmarking
- 10.13.4. Recent Development
- 10.14. Teva Pharmaceutical Industries Ltd. (Israel)
- 10.14.1. Company Overview
- 10.14.2. Financial Performance
- 10.14.3. Product Benchmarking
- 10.14.4. Recent Development
